March 29-30, 2004
Marriott Waterfront HotelBaltimore, Maryland
The Best Pharmaceuticals for Children Act (BPCA) was signed on January 4, 2002, to establish a process for studying on-patent and off-patent drugs for use in pediatric populations, and to improve pediatric therapeutics through collaboration on scientific investigation, clinical study design, weight of evidence, and ethical and labeling issues.
As part of the BPCA collaboration, the NICHD and the U.S. Food and Drug Administration started a Newborn Drug Development Initiative to foster the development of safe and effective drug therapies for preterm and neonatal populations.
This workshop is the first in a series of such meetings for the Newborn Drug Initiative that will help frame the state-of-the-art and define research priorities for pain control and for cardiac, pulmonary, neurologic, and pulmonary diseases and/or conditions.
The workshop will be held at:
Marriott Waterfront Hotel700 Aliceanna StreetBaltimore, MD 21202Phone: 410-385-3000
For more information on the hotel, including driving directions, visit the hotel Web site: http://www.marriotthotels.com .
To learn more about the workshop or its content, contact Jan Leahey, NICHD, at 301-496-6593, or Donald Mattison, NICHD, at 301-497-5097.
To learn more about registration and logistics for the workshop, e-mail your contact information and questions to firstname.lastname@example.org.
All related topics